DBV Technologies (FR:DBV)
:DBV
Want to see FR:DBV full AI Analyst Report?
DBV Stock Chart & Stats
€3.62
€0.10(13.73%)
At close: 4:00 PM EST
€3.62
€0.10(13.73%)
Day’s Range― - ―
52-Week Range€1.30 - €4.50
Previous CloseN/A
Volume1.76M
Average Volume (3M)1.12M
Market Cap
€911.13M
Enterprise Value€408.77M
Total Cash (Recent Filing)€229.20M
Total Debt (Recent Filing)€6.10M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Jul 29, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding278,352,080
10 Day Avg. Volume2,165,856
30 Day Avg. Volume1,121,838
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)3.28
Price to Sales (P/S)0.00
P/FCF Ratio-4.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.26Price Target Upside-10.08% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-0.17
Revenue Forecast (FY)€3.70M
Bulls Say, Bears Say
Bulls Say
Proprietary EPIT Platform (Viaskin)DBV’s Viaskin EPIT patch is a proprietary, non‑invasive delivery platform that creates a structural competitive advantage. If clinical efficacy and safety are confirmed, the platform could be extended across allergens and indications, supporting durable product pipelines and licensing opportunities.
Low Financial LeverageVery low leverage provides financial flexibility relative to peers, reducing near-term insolvency risk and giving management optionality to pursue regulatory filings, partnerships or staged commercialization investments without high interest burdens that could accelerate cash depletion.
Advancing Regulatory And Development MilestonesPlanned BLA submissions and initiation of the THRIVE infant study are structural de‑risking steps toward commercialization and market expansion. Regulatory filings and pediatric data, if positive, can materially expand addressable market and improve long‑term revenue potential.
Bears Say
No Recurring RevenueDBV is a clinical‑stage company with no current product revenue; persistent large net losses mean operations are not self‑funding. Long‑term viability depends on successful approvals or partnerships; absence of revenue leaves the business exposed to execution and financing risks.
Sustained Negative Cash FlowMaterial, ongoing cash burn shows losses are translating into real outflows rather than accounting items, consuming liquidity and constraining ability to scale development or commercial activities. Continued negative FCF increases likelihood of fundraising and potential dilution.
Funding And Capital‑erosion RiskEven with low debt, persistent operating losses erode equity and create funding pressure. The company may need dilutive equity financings or partnerships to complete regulatory and launch activities, which can slow execution and dilute long‑term shareholder value.
DBV Technologies News
DBV FAQ
What was DBV Technologies’s price range in the past 12 months?
DBV Technologies lowest stock price was €1.30 and its highest was €4.50 in the past 12 months.
What is DBV Technologies’s market cap?
DBV Technologies’s market cap is €911.13M.
When is DBV Technologies’s upcoming earnings report date?
DBV Technologies’s upcoming earnings report date is Jul 29, 2026 which is in 69 days.
How were DBV Technologies’s earnings last quarter?
DBV Technologies released its earnings results on Apr 30, 2026. The company reported -€0.019 earnings per share for the quarter, beating the consensus estimate of -€0.023 by €0.004.
Is DBV Technologies overvalued?
According to Wall Street analysts DBV Technologies’s price is currently Overvalued.
Does DBV Technologies pay dividends?
DBV Technologies does not currently pay dividends.
What is DBV Technologies’s EPS estimate?
DBV Technologies’s EPS estimate is -0.02.
How many shares outstanding does DBV Technologies have?
DBV Technologies has 278,352,080 shares outstanding.
What happened to DBV Technologies’s price movement after its last earnings report?
DBV Technologies reported an EPS of -€0.019 in its last earnings report, beating expectations of -€0.023. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of DBV Technologies?
Currently, no hedge funds are holding shares in FR:DBV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DBV Technologies
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
DBV Stock 12 Month Forecast
Average Price Target
€3.26
▼(-10.08% Downside)
Technical Analysis
Options Prices
Currently, No data available
---